Comprehensive Clinical Update on Chronic Myeloid Leukemia (CML): Pathophysiology, Diagnosis, Risk Stratification, and Evidence-Based Management
Prepared for the practicing hematologist/oncologist — incorporating 2023–2024 guidelines (NCCN, ELN, ESMO) and key recent trials (Eneomab, IRIS-15, OPTIC, ASCEND, FREE-SCIPHY) I. Disease Overview & Molecular Pathogenesis Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm (MPN) originating from a hematopoietic stem cell (HSC) in the bone marrow. Its defining molecular feature is the BCR::ABL1…
